May 08, 2026

Long-Term Risks Revealed for Older Survivors of Childhood Cancers

Survivors of childhood cancer who reach the age of 50 and beyond show continued elevated risks for premature mortality, subsequent cancers, and other chronic health conditions, according to a report p...

The ASCO Post

May 07, 2026

From Sophie Spitz to Molecular Melanocytoma

How one woman's pioneering research transformed pediatric melanoma diagnosis

The Pathologist

May 04, 2026

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

The ASCO Post

May 04, 2026

Atezolizumab in Alveolar Soft Part Sarcoma: Long-Term Follow-up

As reported in the Journal of Clinical Oncology by Chen et al, extended follow-up of the pivotal phase II trial of atezolizumab in patients with alveolar soft part sarcoma showed continued benefit of ...

The ASCO Post

April 23, 2026

Medical Oddities: Chew on This Cancer Prevention Idea

From gum to gut to memory—medicine gets weirdly clever fast 

Conexiant

April 22, 2026

Side Effects: Salt, Steroids, and Second Brains

So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.

Conexiant

April 21, 2026

A Reliable Cold Chain is a Health Equity Issue

Why temperature-controlled logistics is a critical but overlooked foundation of equitable access to medicines

The Medicine Maker

April 19, 2026

Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies

A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

Dana-Farber

April 20, 2026

How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs

“The evidence from our study implicates cannabis as a potential etiologic factor contributing to the rising incidence of breast cancer in young females and testis cancer in older adolescent and young ...

The ASCO Post

April 17, 2026

Does HPV Vaccination Lower Cancer Risk in Males?

A large real-world study found a lower incidence of any HPV-related cancer among vaccinated males

Conexiant